MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ARAV - Aravive Inc
$5.51
-0.39(-6.61%)9:00:00 PM 1/27/2021
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Stock Chart

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/4/2021ARAV
    Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference

    HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the H.C. Wainwright Virtual BioConnect Conference taking place January 11-14, 2021. Aravive’s presentation will be available for viewing on January 11, 2021. The webcast and audio archive of the presentation will be available at http://ir.aravive.com. An archived replay of the webcast will be available for ...

    01/1/2021ARAV
    Aravive Announces Board Member Transition to Advisory Role

    HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be stepping down from the Aravive Board of Directors but will remain an advisor to the company, effective December 31, 2020. This transition will allow Dr. Tabibiazar to focus on a new venture. Dr. Tabibiazar co-founded private Aravive Biologics and served as the Chairman of its board of directors and as P...

    12/8/2020ARAV
    Is ARAV A Good Stock To Buy Now?

    The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

    11/19/2020ARAV
    Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer

    Pivotal Trial Expected to be Initiated During 1Q21HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a Phase 3 trial design for AVB-500 in platinum resistant ovarian cancer (PROC). The global, randomized, double-blind, placebo-controlled adaptive trial is designed to evaluate efficacy and tolerability...

    11/17/2020ARAV
    Here's Why We're Not Too Worried About Aravive's (NASDAQ:ARAV) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

    11/16/2020ARAV
    Aravive to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

    HOUSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present and conduct one-on-one meetings with investors at the Piper Sandler 32nd Annual Virtual Healthcare Conference. Aravive’s presentation will be available for viewing beginning on November 23, 2020 and senior management will participate in one-on-one meetings on December 3, 2020. The webcast and audio archive of ...

    11/10/2020ARAV
    Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020

    HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual Ovarian and Renal Cancer Expert Event on Friday, November 20, 2020 from 9:00 a.m. to 10:30 a.m. ET. Aravive will review its clinical development plans for AVB-500 in platinum resistant ovarian cancer and clear cell renal cell carcinoma. The program will also feature perspectives on the evolving treatmen...